DS
TSHA icon

DRW Securities’s Taysha Gene Therapies TSHA Stock Holding History

DRW Securities’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,389
Closed -$53.3K – 1702
2025
Q3 		$53.3K Buy
+16,389
New +$46.4K ﹤0.01% 1226
2024
Q2 		– Sell
-17,800
Closed -$51.1K – 625
2024
Q1 		$51.1K Buy
+17,800
New +$37.1K ﹤0.01% 355

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DRW Securities's TSHA Position: Q4 2025 in Review

DRW Securities sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 16,389 shares — an estimated $53.3K sold.

DRW Securities first reported a position in TSHA in Q1 2024 and held it in 2 quarters. The position peaked at $53.3K in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • DRW Securities reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • DRW Securities sold 16,389 Taysha Gene Therapies shares in Q4 2025, an estimated $53.3K.
  • DRW Securities first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 2 quarters.
  • DRW Securities's Taysha Gene Therapies position peaked at $53.3K in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.